Wellington-Altus USA’s GSK GSK Stock Holding History

Wellington-Altus USA’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38K	Hold	688	–	–	0.03%	366
2026 Q1	$36.1K	Buy	688 +14	+2%	+$759	0.02%	404
2025 Q4	$33.1K	Buy	+674	New	+$31.4K	0.02%	376

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wellington-Altus USA's GSK Position: Q2 2026 in Review

Wellington-Altus USA held its GSK (GSK) position steady in Q2 2026 at 688 shares worth $38K. The position accounts for 0.03% of the portfolio, ranked #366.

Wellington-Altus USA first reported a position in GSK in Q4 2025 and has held it in 3 quarters since. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Wellington-Altus USA held 688 shares of GSK worth $38K as of Q2 2026.
Wellington-Altus USA left its GSK share count unchanged in Q2 2026.
GSK made up 0.03% of Wellington-Altus USA's portfolio in Q2 2026, its #366 holding.
Wellington-Altus USA first reported a position in GSK in Q4 2025 and has held it in 3 quarters since.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Wellington-Altus USA's 13F filing for Q2 2026, filed 17 Sep 2026.